Department of Pharmaceutical Business and Administrative Sciences, MCPHS University, Boston, MA, 02115, USA.
Division of General Internal Medicine and Primary Care, Brigham and Women's Hospital, Boston, MA, USA.
Obes Surg. 2018 Aug;28(8):2203-2214. doi: 10.1007/s11695-017-3100-0.
In the USA, three types of bariatric surgeries are widely performed, including laparoscopic sleeve gastrectomy (LSG), laparoscopic Roux-en-Y gastric bypass (LRYGB), and laparoscopic adjustable gastric banding (LAGB). However, few economic evaluations of bariatric surgery are published. There is also scarcity of studies focusing on the LSG alone. Therefore, this study is evaluating the cost-effectiveness of bariatric surgery using LRYGB, LAGB, and LSG as treatment for morbid obesity.
A microsimulation model was developed over a lifetime horizon to simulate weight change, health consequences, and costs of bariatric surgery for morbid obesity. US health care prospective was used. A model was propagated based on a report from the first report of the American College of Surgeons. Incremental cost-effectiveness ratios (ICERs) in terms of cost per quality-adjusted life-year (QALY) gained were used in the model. Model parameters were estimated from publicly available databases and published literature.
LRYGB was cost-effective with higher QALYs (17.07) and cost ($138,632) than LSG (16.56 QALYs; $138,925), LAGB (16.10 QALYs; $135,923), and no surgery (15.17 QALYs; $128,284). Sensitivity analysis showed initial cost of surgery and weight regain assumption were very sensitive to the variation in overall model parameters. Across patient groups, LRYGB remained the optimal bariatric technique, except that with morbid obesity 1 (BMI 35-39.9 kg/m) patients, LSG was the optimal choice.
LRYGB is the optimal bariatric technique, being the most cost-effective compared to LSG, LAGB, and no surgery options for most subgroups. However, LSG was the most cost-effective choice when initial BMI ranged between 35 and 39.9 kg/m.
在美国,广泛开展了三种减重手术,包括腹腔镜袖状胃切除术(LSG)、腹腔镜 Roux-en-Y 胃旁路术(LRYGB)和腹腔镜可调胃束带术(LAGB)。然而,发表的减重手术经济评价很少,也很少有研究单独关注 LSG。因此,本研究评估了 LRYGB、LAGB 和 LSG 作为治疗病态肥胖的减肥手术的成本效益。
采用微观模拟模型,在终生范围内模拟减重手术对病态肥胖的体重变化、健康后果和成本。采用美国医疗保健前瞻性。该模型基于美国外科医师学院的第一份报告进行了传播。模型中使用了增量成本效益比(ICER),即每获得一个质量调整生命年(QALY)的成本。模型参数是根据公开数据库和已发表文献进行估计的。
LRYGB 在 QALY(17.07)和成本(138632 美元)方面优于 LSG(16.56 QALY;138925 美元)、LAGB(16.10 QALY;135923 美元)和无手术(15.17 QALY;128284 美元)。敏感性分析表明,手术初始成本和体重反弹假设对整体模型参数的变化非常敏感。在各患者组中,LRYGB 仍然是最佳的减肥手术技术,除了肥胖 1 组(BMI 35-39.9 kg/m)患者外,LSG 是最佳选择。
与 LSG、LAGB 和无手术选择相比,LRYGB 是最具成本效益的减肥手术技术,对于大多数亚组来说是最有效的。然而,当初始 BMI 范围在 35 到 39.9 kg/m 之间时,LSG 是最具成本效益的选择。